Alnylam, Qiagen, Sigma-Aldrich, Genospectra | GenomeWeb

Alnylam Reports Increased Q4, 2005
Losses Amid Higher R&D Spending

Alnylam Pharmaceuticals this week reported its financial results for the fourth quarter and full-year 2005, posting widening losses amid increased research and development spending.

For the fourth quarter, Alnylam's net loss rose to $14.5 million, or $0.56 per share, from $5.7 million, or $0.29 per share, in the year-ago quarter. For 2005, the company's net loss jumped to $42.9 million, or $1.96 per share, from $35.4 million, or $2.98 per share, the year before.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.